Spinogenix

In the majority of neurodegenerative conditions, there is a loss of connections - known as synapses - among nerve cells, a progression that contributes to declines in cognitive and motor function that define these conditions. At Spinogenix, we are in the process of developing innovative small molecule drugs (SPGs) that are first of their kind and aim to restore synapses in order to enhance and potentially revive cognitive and motor function. Our approach is distinct and tailored for conditions affecting the central nervous system. Spinogenix is working on a new category of treatments to revive memory and motor abilities that have been lost in neurodegenerative and psychiatric conditions.